

Appendix A: Methodology

The goal of this paper was to analyze changes and trends across four of the most editions of the WHO's Essential Medicines List. Specific objectives of this project were to: 1) analyze the percentage of patented drugs on the EML for the 19th (2015), 20th (2017), 21st (2019), and 22nd editions of the EML; and 2) determine, to the extent possible, the patent status for each drug on the EML with regard to a sample of 150 lower income countries of medicines on the 21st EML as well as the existence of any voluntary licensing program.

Objective 1

We largely employed the methodology used by Beall and Attaran (2016) to determine which drugs were patented and where. For the sake of timeliness, we were able to abbreviate some steps using public resources that have become available since the time of that study.

The steps to determine whether a drug on the EML is “patented” according to the Beall-Attaran methodology can be summed up as follows:

- 1) First, check to determine if a drug was approved for sale in the US or Canada.
- 2) Second, check whether the drug was listed as patented in the Orange Book or on Health Canada's Patent Registry.
- 3) Third, check whether generics were available for the use indicated on the EML. If the drug was approved for sale in the US or Canada, listed as patented, and no generics were available, then it counted as patented. If it was listed as unpatented and/or generics were available, it was considered not subject to patent.
- 4) If the drug was not approved for sale in the US or Canada, or a biologic, Beall-Attaran performed further research using a commercial database to determine patent status. We were able to use the MedsPal Database for much of this research, and for about ten drugs not listed on MedsPal, we used a commercial database, DrugPatentWatch, which focuses on providing specialized information regarding drug patents.
- 5) If the drug was patented, Beall and Attaran also used a commercial database to determine where patents existed, how many, and the date of first and last expiration. Here, we were able to rely on MedsPal and DrugPatentWatch.
- 6) Lastly, Beall and Attaran verified results with pharmaceutical manufacturers, as there are known to be gaps in databases. As Beall and Attaran acknowledge, this step was a challenging and lengthy process. Instead, we used a newer public database, PatInformed, which contains information submitted by most pharmaceutical manufacturers to the World Intellectual Property Organization regarding the patent status of their drugs worldwide. One stated goal of PatInformed is to help medicine procurement agencies to determine if a drug is under patent. Presumably, innovative companies thus have an incentive to ensure that the information in PatInformed is complete. We considered PatInformed to play a similar role as making direct inquiries to pharmaceutical companies regarding patent status of medicines, and thus an acceptable substitute for Beall & Attaran's step of direct verification. Moreover, the availability of MedsPal and DrugPatentWatch left far fewer gaps in the data.

Objective 2

Using the MedsPal database, supplemented by DrugPatentWatch for about 10 drugs, we determined how many active patent listings, if any, exist in the relevant jurisdictions, as well as the first and last dates of expiration for said patents. Active filings are those listed as “filed,” “filed but opposed,” “granted,” “granted but opposed,” or “rejected but under appeal” with an expected expiration date of February 1, 2022, or later. The relevant jurisdictions are low and middle income countries as that term is defined by the World Bank. These were also the 150 lower income countries listed in MedsPal, so that was where data was available.

Afghanistan	Cuba	Liberia	Samoa
Albania	Djibouti	Libya	Sao Tome and
Algeria	Dominica	Madagascar	Principe
Angola	Dominican Republic	Malawi	Senegal
Anguilla	Ecuador	Malaysia	Serbia
Antigua and Barbuda	Egypt	Maldives	Seychelles
Argentina	El Salvador	Mali	Sierra Leone
Armenia	Equatorial Guinea	Marshall Islands	Solomon Islands
Aruba	Eritrea	Mauritania	Somalia
Azerbaijan	Eswatini (formerly	Mauritius	South Africa
Bahamas	Swaziland)	Mexico	South Sudan
Bangladesh	Ethiopia	Micronesia	Sri Lanka
Barbados	Fiji	Moldova, Republic	Sudan
Belarus	Gabon	of	Suriname
Belize	Gambia	Mongolia	Syrian Arab
Benin	Georgia	Montenegro	Republic
Bhutan	Ghana	Morocco	Tajikistan
Bolivia	Grenada	Mozambique	Tanzania, United
Bosnia and	Guatemala	Myanmar	Republic of
Herzegovina	Guinea	Namibia	Thailand
Botswana	Guinea-Bissau	Nauru	Timor-Leste
Brazil	Guyana	Nepal	Togo
Burkina Faso	Haiti	Nicaragua	Tonga
Burundi	Honduras	Niger	Trinidad and Tobago
Cabo Verde	India	Nigeria	Tunisia
Cambodia	Indonesia	North Macedonia	Turkey
Cameroon	Iran (Islamic	Pakistan	Turkmenistan
Central African	Republic of)	Palau	Turks and Caicos
Republic	Iraq	Panama	Islands
Chad	Jamaica	Papua New Guinea	Tuvalu
Chile	Jordan	Paraguay	Uganda
China	Kazakhstan	Peru	Ukraine
Colombia	Kenya	Philippines	United Arab
Comoros	Kiribati	Russian Federation	Emirates
Congo	Korea, DPR of	Rwanda	Uruguay
Congo, the	Kosovo	Saint Kitts and Nevis	Uzbekistan
democratic Republic	Kyrgyz Republic	Saint Lucia	Vanuatu
of the	Lao PDR	Saint Vincent and	Venezuela
Costa Rica	Lebanon	the	Viet Nam
Côte d’Ivoire	Lesotho	Grenadines	

Virgin Islands
(British)

West Bank and Gaza
Yemen

Zambia
Zimbabwe

All information on the relevant medicine was downloaded from the database then sorted. Irrelevant patents (i.e. – patents for other combinations, forms not covered on the EML, jurisdictions not within our scope) and inactive patents (expired, withdrawn, rejected, etc.) were removed first. If any duplicate patents existed within one jurisdiction, they were also removed.

Once a complete list of active patents, jurisdictions, and expected expiration dates was compiled, we determined the total number of jurisdictions with active filings, total number of active filings, first date of expiration, and last date of expiration for each medicine. Since all active filings were considered, the last date of expiration may be for a patent that is not yet granted. For those medicines researched using MedsPal, any relevant MPP licenses, bilateral licenses, and/or commitments to not enforce were noted next to the jurisdictions covered for that item.

Some MPP licenses, bilateral licenses, and commitments to not enforce cover multiple patents and medicines. For example, one commitment to not enforce covers lopinavir+ritonavir and ritonavir. Likewise, dolutegravir and dolutegravir+lamivudine+tenofovir are covered by the same MPP and bilateral licenses.

Appendix B:

Details of Patents on EML Medicines in Lower Income Countries

Abacavir

There are 2 jurisdictions with 2 active filings. The first date of expiration was 2009; the latest patent is estimated to expire in 2023.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Belarus	1	14/05/2023	EA199900944	No
Kazakhstan	1	27/08/2022	EA199900944	No

Anti-rabies Virus Monoclonal Antibodies

As of this writing, this treatment includes two anti-RV monoclonal anti-body treatments. The first is **17C7** (also known as RAB1, SII RMAB or the tradename Rabisheld) and the second is a combination of two monoclonal **antibodies docaravimab + miromavimab** (also known as M777-16-3/62-71-3 or by the tradenames Rabimab or Twinrab). Both of these treatments are under patent. At the time of writing, two other anti-RV monoclonal anti-body treatments are in clinical trials, CR57 (also known as rhRIG) and CTB011 and CTB012 (also known as SYN023). See *Application for Inclusion of Anti-Rabies Virus Monoclonal Antibodies to the World Health Organization's Model Lists of Essential Medicines and Essential Medicines for Children*, available at https://cdn.who.int/media/docs/default-source/essential-medicines/2021-eml-expert-committee/applications-for-addition-of-new-medicines/a.26_rabies-mabs.pdf?sfvrsn=f674181b_4

Anti-rabies Virus Monoclonal Antibodies: 17C7 ARV Mab

There are 6 jurisdictions with 6 active filings. All patents are estimated to expire in 2026.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Brazil	1	10/08/2026	BRPI0606790	No
China	1	10/08/2026	CN101133158	No
South Africa	1	10/08/2026	ZA200707339	No
Russian Federation	1	10/08/2026	RS 53239	No
Mexico	1	10/08/2026	MX2007009273	No

Montenegro	1	10/08/2026	ME01785	No
------------	---	------------	---------	----

Anti-rabies Virus Monoclonal Antibodies: *Docaravimab* + *Miromavimab* ARV Mab Cocktail

There are 4 jurisdictions with 4 active filings. The latest patent is estimated to expire in 2039.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
China	1	24/10/2039	CN113226372	No
India	1	2/01/2038	IN201821041598	No
Peru	1	24/10/2039	PE20211056	No
Phillippines	1	24/10/2039	PH12021550987	No

Aprepitant

There are 27 jurisdictions with 29 total active filings. The first date of expiration was 2013; the latest patent is estimated to expire in 2022.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Albania	1	9/12/2022	EP02796109	No
Algeria	1	9/12/2022	DZ040145	No
Belarus	2	9/12/2022	EA200400794	No
Brazil	1	9/12/2022	BRPI0214786	No
Chile	1	13/05/2026	CL200202791	No
China	1	9/12/2022	CN02827814	No
Georgia	1	9/12/2022	GEAP2002005622	No
India	1	9/12/2022	IN1265/CHENP/2004	No
Indonesia	1	9/12/2022	IDW00200401196	No
Jordan	1	3/12/2022	JOP20020126	No
Kazakhstan	1	9/12/2022	EA200400794	No
Malaysia	1	4/12/2022	MYPI20024570	No
Mexico	2	9/12/2022	MXPA2006/015183	No

Montenegro	1	9/12/2022	MEP68408	No
North Macedonia	1	9/12/2022	EP02796109	No
Pakistan	1	3/12/2022	PK1031/2002	No
Philippines	1	9/12/2022	PH12004500819	No
Russian Federation	1	9/12/2022	EA200400794	No
Serbia	1	9/12/2022	YUP50404	No
South Africa	1	8/12/2022	ZA200404012	No
Thailand	1	3/12/2022	TH0201004524	No
Turkey	1	9/12/2022	EP02796109	No
Ukraine	1	9/12/2022	UA20040705610	No
United Arab Emirates	1	9/12/2022	AE188/2004	No
Uzbekistan	1	9/12/2022	UZIAP20040271	No
Venezuela	1	5/12/2022	VE2002002393	No
Viet Nam	1	9/12/2022	VN1200400561	No

Atazanavir + Ritonavir

There are only two jurisdictions (Mexico and Thailand) with two total active filings for this specific combination patent, and both are estimated to expire in 2028. However, there are 26 jurisdictions with 49 total active filings for patents related to atazanavir or ritonavir, individually, which affect this combination. The first date of expiration was 2012; the latest patent is estimated to expire in 2029.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Argentina	1	03/05/2025	ARP150100592	Commitment to not enforce ritonavir
Belize	1	21/02/2026	BZ481.07	Commitment to not enforce ritonavir
Bosnia and Herzegovina	1	03/05/2025	EP05744537	Commitment to not enforce ritonavir
Brazil	2	03/05/2025	BRPI0509595	Commitment to not enforce ritonavir
Chile	1	04/05/2025	CL200501057	Commitment to not enforce ritonavir
China	2	03/05/2025	CN200580022550	Commitment to not enforce ritonavir

Ecuador	1	23/08/2024	ECSP066397	Commitment to not enforce ritonavir
Guatemala	1	05/07/2026	GT200600295	Commitment to not enforce ritonavir
Lebanon	1	13/06/2028	LB8336	Commitment to not enforce ritonavir
Mexico	6	20/06/2028	MX2009013461	Commitment to not enforce ritonavir
Montenegro	2	03/05/2025	MEP65315	Commitment to not enforce ritonavir
Nicaragua	2	21/02/2026	NI200700219	Commitment to not enforce ritonavir
North Macedonia	1	03/05/2025	EP05744537	Commitment to not enforce ritonavir
Panama	1	23/02/2026	PA8664801	Commitment to not enforce ritonavir
Philippines	3	21/02/2026	PH12007501802	Commitment to not enforce ritonavir
Russian Federation	1	03/05/2025	RU2006142768	Commitment to not enforce ritonavir
Serbia	3	03/05/2025	EP05744537	Commitment to not enforce ritonavir
South Africa	5	21/02/2026	ZA200707022	Commitment to not enforce ritonavir; MPP licenses for atazanavir and ritonavir
Sri Lanka	2	21/02/2026	LK14598	Commitment to not enforce ritonavir
Thailand	2	20/06/2028	TH0801003176	No
Turkey	2	20/06/2028	EP08771562	Commitment to not enforce ritonavir
United Arab Emirates	2	22/06/2028	GCP2008011117	Commitment to not enforce ritonavir
Uruguay	2	14/09/2029	UY32116	Commitment to not enforce ritonavir
Venezuela	2	22/02/2026	VE2006000342	Commitment to not enforce ritonavir; MPP licenses for atazanavir and ritonavir
Viet Nam	2	21/02/2026	VN1200701909	Commitment to not enforce ritonavir

Azithromycin

There are 62 jurisdictions with 71 total active filings. The latest patent is estimated to expire in 2023.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Argentina	1	2023-12-04	045630	No
Armenia	2	2023-12-04	010110	No
Azerbaijan	2	2023-12-04	010110	No
Belarus	2	2023-12-04	010110	No
Benin	1	2023-12-04	12858	No
Botswana	1	2023-12-04	2218	No
Brazil	1	2023-12-04	PI0403935	No
Burkina Faso	1	2023-12-04	12858	No
Cameroon	1	2023-12-04	12858	No
Central African Republic	1	2023-12-04	12858	No
Chad	1	2023-12-04	12858	No
Chile	1	2023-12-04	2004001501	No
China	1	2023-12-04	1697648	No
Congo	1	2023-12-04	12858	No
Costa Rica	1	2023-12-04	7500	No
Côte d'Ivoire	1	2023-12-04	12858	No
Dominican Republic	1	2023-12-04	P2004000994	No
Ecuador	1	2023-12-04	SP045351	No
Equatorial Guinea	1	2023-12-04	12858	No
Eswatini	1	2023-12-04	2218	No
Gabon	1	2023-12-04	12858	No
Gambia	1	2023-12-04	2218	No
Georgia	1	2023-12-04	P20074056	No
Ghana	1	2023-12-04	2218	No
Guatemala	1	2023-12-04	200400183	No
Guinea	1	2023-12-04	12858	No

Guinea-Bissau	1	2023-12-04	12858	No
Kazakhstan	2	2023-12-04	010110	No
Kenya	1	2023-12-04	2218	No
Korea, DPR of	2	2023-12-04	100906290	No
Kyrgyz Republic	2	2023-12-04	010110	No
Lesotho	1	2023-12-04	2218	No
Liberia	1	2023-12-04	2218	No
Malawi	1	2023-12-04	2218	No
Mali	1	2023-12-04	12858	No
Mauritania	1	2023-12-04	12858	No
Mexico	1	2023-12-04	PA04009424	No
Morocco	1	2023-12-04	27848	No
Mozambique	1	2023-12-04	2218	No
Namibia	1	2023-12-04	2218	No
Niger	1	2023-12-04	12858	No
Panama	1	2023-12-04	8611501	No
Peru	1	2023-12-04	20050573	No
Russian Federation	2	2023-12-04	010110	No
Rwanda	1	2023-12-04	2218	No
Sao Tome & Principe	1	2023-12-04	2218	No
Senegal	1	2023-12-04	12858	No
Serbia	1	2023-12-04	84704	No
Sierra Leone	1	2023-12-04	2218	No
Somalia	1	2023-12-04	2218	No
South Africa	1	2023-12-04	200408075	No
Sudan	1	2023-12-04	2218	No
Tajikistan	2	2023-12-04	010110	No
Tanzania	1	2023-12-04	2218	No
Togo	1	2023-12-04	12858	No
Tunisia	1	2023-12-04	SN05319	No
Turkmenistan	2	2023-12-04	010110	No
Uganda	1	2023-12-04	2218	No
Ukraine	1	2023-12-04	78793	No

Uruguay	1	2023-12-04	28509	No
Zambia	1	2023-12-04	2218	No
Zimbabwe	1	2023-12-04	2218	No

Bedaquiline

There are 79 jurisdictions with 352 active filings. The first date of expiration is estimated to occur in 2023; the latest patent is estimated to expire in 2028.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Albania	8	1/26/36	EP16701516	No
Argentina	1	7/24/23	ARP030102655	No
Armenia	6	1/26/36	EA201791701	Yes, bilateral license
Azerbaijan	6	1/26/36	EA201791701	Yes, bilateral license
Belarus	6	1/26/36	EA201791701	Yes, bilateral license
Benin	5	1/26/36	OA1201700283	No
Bosnia and Herzegovina	6	1/26/36	EP16701516	No
Botswana	5	1/26/36	AP/P/2017/010050	No
Brazil	6	1/26/36	BR112017015784	No
Burkina Faso	5	1/26/36	OA1201700283	No
Cameroon	5	1/26/36	OA1201700283	No
Central African Republic	5	1/26/36	OA1201700283	No
Chad	5	1/26/36	OA1201700283	No
Chile	3	12/3/27	CL2007003472	No
China	7	1/26/36	CN201680007314	No
Colombia	1	12/8/25	COPCT/EP2005/056594	No
Comoros	1	1/26/36	OA1201700283	No
Congo	5	1/26/36	OA1201700283	No
Côte d'Ivoire	5	1/26/36	OA1201700283	No
Egypt	1	7/21/23	EG2003000704	No
Equatorial Guinea	5	1/26/36	OA1201700283	No
Eswatini	5	1/26/36	AP/P/2017/010050	No

Gabon	5	1/26/36	OA1201700283	No
Gambia	5	1/26/36	AP/P/2017/010050	No
Ghana	5	1/26/36	AP/P/2017/010050	No
Guinea	5	1/26/36	OA1201700283	No
Guinea-Bissau	5	1/26/36	OA1201700283	No
India	5	1/26/36	IN201727030045	No
Indonesia	5	1/26/36	ID201704901	No
Jordan	3	12/2/27	JOP20070511	No
Kazakhstan	6	1/26/36	EA201791701	Yes, bilateral license
Kenya	5	1/26/36	AP/P/2017/010050	No
Kosovo	4	8/11/28	KV2008048	No
Kyrgyz Republic	6	1/26/36	EA201791701	Yes, bilateral license
Lebanon	3	12/4/27	LB200708103	No
Lesotho	5	1/26/36	AP/P/2017/010050	No
Liberia	1	1/26/36	AP/P/2017/010050	No
Malawi	5	1/26/36	AP/P/2017/010050	No
Malaysia	4	12/3/27	MYPI20092284	No
Mali	5	1/26/36	OA1201700283	No
Mauritania	5	1/26/36	OA1201700283	No
Mexico	6	1/26/36	MX2017009681	No
Moldova, Republic of	6	1/26/36	EP16701516	Yes, bilateral license
Montenegro	6	1/26/36	EP16701516	No
Morocco	1	1/26/36	EP16701516	No
Mozambique	5	1/26/36	AP/P/2017/010050	No
Namibia	4	1/26/36	AP/P/2017/010050	No
Nicaragua	1	12/8/25	NI200700146	No
Niger	5	1/26/36	OA1201700283	No
North Macedonia	7	1/26/36	EP16701516	No
Pakistan	7	12/3/27	PK1403/2007	No
Panama	3	12/5/27	PA87597	No
Peru	2	1/26/36	PE2017001255	No
Philippines	6	1/26/36	PH12017501331	No
Russian Federation	6	1/26/36	EA201791701	Yes, bilateral license

Rwanda	1	1/26/36	AP/P/2017/010050	No
Sao Tome & Principe	1	1/26/36	AP/P/2017/010050	No
Senegal	5	1/26/36	OA1201700283	No
Serbia	6	1/26/36	EP16701516	No
Sierra Leone	5	1/26/36	AP/P/2017/010050	No
South Africa	6	1/26/36	ZA201705088	No
Sri Lanka	4	12/3/27	LK15376	No
Sudan	5	1/26/36	AP/P/2017/010050	No
Tajikistan	6	1/26/36	EA201791701	Yes, bilateral license
Tanzania	5	1/26/36	AP/P/2017/010050	No
Thailand	4	1/26/36	TH17001004168	No
Togo	5	1/26/36	OA1201700283	No
Trinidad and Tobago	1	12/8/25	TT/A/2007/00134	No
Turkey	6	1/26/36	EP16701516	No
Turkmenistan	6	1/26/36	EA201791701	Yes, bilateral license
Uganda	5	1/26/36	AP/P/2017/010050	No
Ukraine	6	1/26/36	UAA201708632	Yes, bilateral license
United Arab Emirates	4	12/5/27	GC200709625	No
Uruguay	1	12/5/27	UY30762	No
Venezuela	3	12/6/27	VE2007002659	No
Viet Nam	3	12/3/27	VN1200900771	No
Zambia	5	1/26/36	AP/P/2017/010050	No
Zimbabwe	5	1/26/36	AP/P/2017/010050	No

Bendamustine

There are 22 jurisdictions with 29 active filings. The first date of expiration is expected to occur in 2026; the latest patent is estimated to expire in 2029.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Albania	1	3/26/29	EP09723661	No
Armenia	1	1/13/26	EA200701511	No
Azerbaijan	1	1/13/26	EA200701511	No

Belarus	1	1/13/26	EA200701511	No
Bosnia and Herzegovina	1	3/26/29	EP09723661	No
Brazil	1	1/13/26	BRPI0606332	No
Chile	1	1/13/26	CL200600074	No
China	5	9/23/29	CN200980137977	No
Egypt	1	1/12/26	EG2007000689	No
Kazakhstan	1	1/13/26	EA200701511	No
Kyrgyz Republic	1	1/13/26	EA200701511	No
Malaysia	1	1/13/26	MYPI20060159	No
Mexico	4	9/23/29	MX2011002936	No
Moldova, Republic of	1	1/13/26	EA200701511	No
North Macedonia	1	3/26/29	EP09723661	No
Philippines	1	1/13/26	PH12007501445	No
Russian Federation	1	1/13/26	EA200701511	No
Serbia	1	3/26/29	EP09723661	No
South Africa	1	1/13/26	ZA200705793	No
Tajikistan	1	1/13/26	EA200701511	No
Turkmenistan	1	1/13/26	EA200701511	No
Ukraine	1	1/13/26	UAA200709242	No

Carbetocin

There are 13 jurisdictions with 30 active filings. The first date of expiration is expected to occur in 2031; the latest patent is estimated to expire in 2031.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Albania	3	9/29/31	EP17169328	No
Algeria	1	9/29/31	DZ130183	No
Brazil	2	9/29/31	BR122021001123	No
China	2	9/29/31	CN201610930206	No
India	1	9/29/31	IN2471/DELNP/2013	No
Jordan	3	9/28/31	JOP20110297	No
Mexico	4	11/29/31	MX2016014747	No

North Macedonia	3	9/29/31	EP11776530	No
Russian Federation	2	9/29/31	RU2016143751	No
Serbia	4	9/29/31	EP17169301	No
South Africa	1	9/29/31	ZA201301991	No
Turkey	3	9/29/31	EP11776530	No
United Arab Emirates	1	9/29/31	AEP328/2013	No

Cefiderocol

There are 22 jurisdictions with 51 active filings. The first date of expiration is expected to occur in 2028; the latest patent is estimated to expire in 2034.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Armenia	4	31/10/2028	EA019520	No
Azerbaijan	4	31/10/2028	EA019520	No
Belarus	4	31/10/2028	EA019520	No
Brazil	2	31/10/2028	EA019520	No
Chile	1	31/10/2028	EA019520	No
China	3	31/10/2028	EA019520	No
Colombia	1	31/10/2028	EA019520	No
Costa Rica	1	31/10/2028	EA019520	No
Kazakhstan	4	04/09/2034	1.12017E+11	No
Kyrgyz Republic	4	04/09/2034	106687116	No
Malaysia	1	04/09/2034	2017002790	No
Mexico	2	04/09/2034	40585	No
Montenegro	1	04/09/2034	12017500435	No
Morocco	2	31/10/2028	2011000939	No
Peru	1	31/10/2028	6331443	No
Philippines	1	31/10/2028	20110144	No
Russian Federation	4	31/10/2028	155655	No
Serbia	1	31/10/2028	2666	No
South Africa	1	31/10/2028	20120010	No
Tajikistan	4	31/10/2028	55365	No
Turkmenistan	4	31/10/2028	201102024	No

Ukraine	1	31/10/2028	105190	No
---------	---	------------	--------	----

Ceftazidime + Avibactam

There are no patents specifically for this combination; all active patents are related to either ceftazidime or avibactam individually. There are 60 jurisdictions with 96 total active filings relevant to the compounds that make up this combination. The first date of expiration was 1999; the latest patent is estimated to expire in 2033.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Albania	5	6/15/32	EP12727922	No
Algeria	1	1/27/23	DZ040194	No
Anguilla	1	1/27/23	AI/A/2013/00142	No
Argentina	1	6/15/32	ARP120102159	No
Benin	1	1/27/23	OA1200400200	No
Bolivia (Plurinational State of)	1	1/27/23	BO230015	No
Bosnia and Herzegovina	2	1/27/33	BA041758	No
Brazil	4	6/15/32	BR112013032415	No
Burkina Faso	1	1/27/23	OA1200400200	No
Cameroon	1	1/27/23	OA1200400200	No
Central African Republic	1	1/27/23	OA1200400200	No
Chad	1	1/27/23	OA1200400200	No
Chile	2	6/17/26	CL200300134	No
China	6	6/15/32	CN201280029765	No
Congo	1	1/27/23	OA1200400200	No
Costa Rica	1	1/27/23	CR7387	No
Côte d'Ivoire	1	1/27/23	OA1200400200	No
Egypt	1	1/26/23	EG2003000062	No
Equatorial Guinea	1	1/27/23	OA1200400200	No
Fiji	1	1/27/23	FJ03709903.3	No
Gabon	1	1/27/23	OA1200400200	No
Gambia	1	1/27/23	GMPI20015	No

Grenada	1	1/27/23	GD03709903.3	No
Guinea	1	1/27/23	OA1200400200	No
Guinea-Bissau	1	1/27/23	OA1200400200	No
India	2	10/8/30	IN586/MUMNP/2012	No
Indonesia	1	1/27/23	IDW00200401585	No
Jordan	1	12/29/22	JOP20020138	No
Kenya	1	1/27/23	KEPCT/FR03/00243	No
Kiribati	1	1/27/23	KI25/13	No
Lebanon	1	1/3/23	LB6630	No
Malaysia	3	6/15/32	MYPI2013702441	No
Mali	1	1/27/23	OA1200400200	No
Mauritania	1	1/27/23	OA1200400200	No
Mexico	3	6/15/32	MX2013014114	No
Montenegro	1	10/8/30	EP17182561	No
Morocco	1	1/27/23	MA27777	No
Niger	1	1/27/23	OA1200400200	No
Nigeria	1	1/16/23	NG35/2003	No
North Macedonia	4	10/8/30	EP17182561	No
Pakistan	1	1/27/23	PK00492003	No
Paraguay	1	1/27/23	PY1561/2003	No
Peru	1	1/27/23	PE2003000080	No
Philippines	1	1/27/23	PH12004501030	No
Russian Federation	6	6/15/32	RU2017102358	No
Samoa	1	1/27/23	WS03709903.3	No
Senegal	1	1/27/23	OA1200400200	No
Serbia	4	6/15/32	EP12727922	No
South Africa	1	1/27/23	ZA200405607	No
Thailand	1	1/24/23	TH0301000234	No
Togo	1	1/27/23	OA1200400200	No
Tunisia	1	7/23/24	TNSN04137	No
Turkey	6	6/15/32	EP12727922	No
Turks and Caicos Islands	1	1/27/23	TC03709903.3	No

Ukraine	1	1/27/23	UA20040807144	No
United Arab Emirates	2	1/27/23	AEPCT/FR03/00243	No
Venezuela	2	1/28/23	VE19970003	No
Viet Nam	1	1/27/23	VN1200400849	No
Virgin Islands (British)	1	1/27/23	VG03709903.3	No

Daclatasvir

There are 16 jurisdictions with 34 total active filings. The first date of expiration is expected to occur in 2027; the latest patent is estimated to expire in 2030.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Argentina	2	8/9/27	ARP070103535	No
Brazil	1	8/9/27	BRPI0716483	No
Chile	3	5/10/32	CL2012001230	Commitment to not enforce
China	2	8/9/27	CN200780037723	No
Colombia	1	8/9/27	CO09013323	Commitment to not enforce
India	3	11/2/30	IN3999/CHENP/2012	Yes, MPP license
Lebanon	1	8/9/27	LB200707962	No
Mexico	4	11/2/30	MX2012005246	Commitment to not enforce
Peru	2	8/8/28	PE2008001326	Commitment to not enforce
Russian Federation	2	7/14/30	EA201000196	No
South Africa	2	7/31/28	ZA201000843	Yes, MPP license
Thailand	2	8/8/28	TH0801004156	No
Tunisia	1	5/11/32	TN2012000214	Yes, MPP license
Turkey	3	8/9/27	EP14168065	No
United Arab Emirates	3	8/9/28	GC2008011478	No
Venezuela	2	8/6/28	VE200801614	Commitment to not enforce

Dasabuvir

There are 6 jurisdictions with 8 total active filings. The first date of expiration is expected to occur in 2028; the latest patent is estimated to expire in 2030.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
China	1	9/17/28	CN200880113534	No
Mexico	1	9/17/28	MX2010002902	No
Russian Federation	1	4/21/30	RU2010114827	No
South Africa	1	9/17/28	ZA201002689	No
Turkey	3	9/17/28	EP12182277	No
Ukraine	1	9/17/28	UA2010004147	No

Delamanid

There are 17 jurisdictions with 38 total active filings. The first date of expiration is expected to occur in 2023; the latest patent is estimated to expire in 2031.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Argentina	1	10/9/23	ARP030103673	No
Bangladesh	2	10/5/26	BD20060220	Yes, bilateral license (Mylan)
Belarus	2	5/2/28	BY20080575	Yes, bilateral license (R-Pharm)
Brazil	2	7/19/26	BRPI0613883	Yes, bilateral license (Mylan)
China	4	1/28/31	CN201180006814	No
India	2	7/19/26	IN9790/DELNP/2007	Yes, bilateral license (Mylan)
Indonesia	1	7/19/26	IDW00200800233	No
Malaysia	2	7/26/26	MYPI20063579	Yes, bilateral license (Mylan)
Mexico	3	1/28/31	MX2012008501	Yes, bilateral license (Mylan)
Pakistan	2	10/3/26	PK200601314	Yes, bilateral license (Mylan)

Philippines	2	11/26/27	PH12007502673	No
Russian Federation	3	7/19/31	RU2008107595	Yes, bilateral license (R-Pharm)
South Africa	4	1/28/31	ZA201204802	Yes, bilateral license (Mylan)
Thailand	2	10/3/26	TH0601004877	No
Turkey	3	1/28/31	EP11706939	No
Ukraine	2	7/19/26	UAA200802496	Yes, bilateral license (R-Pharm)
Viet Nam	1	7/19/26	VN200800490	No

Dolutegravir

There are 27 jurisdictions with 56 active filings. The first date of expiration is expected to occur in; the latest patent is estimated to expire in 2031.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Algeria	1	28/04/2026	DZ070738	No
Armenia	1	28/04/2031	EA200702080	Yes, MPP and bilateral licenses
Azerbaijan	1	14/12/2026	EA200702080	No
Belarus	1	01/10/2030	EA200702080	No
Brazil	2	15/09/2030	BRPI0610030	No
China	7	09/12/2029	CN200980149670	No
Colombia	2	28/04/2026	CO07115501A	No
Egypt	1	28/04/2026	EG2007011167	Yes, MPP and bilateral licenses
India	5	09/12/2029	IN1971/KOLNP/2011	Yes, MPP and bilateral licenses
Indonesia	3	08/12/2029	IDP00201403774	Yes, MPP and bilateral licenses
Kazakhstan	1	04/02/2030	EA200702080	No
Kyrgyz Republic	1	28/04/2026	EA200702080	Yes, MPP and bilateral licenses
Malaysia	1	31/10/2027	MY200701883	No
Mexico	5	08/12/2029	MX2013008013	No

Moldova, Republic of	1	23/04/2030	EA200702080	Yes, MPP and bilateral licenses
Morocco	1	28/04/2026	MA30388	Yes, MPP and bilateral licenses
Nigeria	1	28/04/2026	NG2007/12/473	Yes, MPP and bilateral licenses
North Macedonia	1	09/12/2029	EP19204147	No
Philippines	1	28/04/2026	PH12007502373	Yes, MPP and bilateral licenses
Russian Federation	3	08/12/2029	RU2013153004	No
South Africa	1	28/04/2026	ZA200708970	Yes, MPP and bilateral licenses
Tajikistan	1	28/04/2026	EA200702080	Yes, MPP and bilateral licenses
Trinidad and Tobago	2	28/04/2026	TT200700254	No
Turkey	8	09/12/2029	EP19204147	No
Turkmenistan	1	28/04/2026	EA200702080	Yes, MPP and bilateral licenses
Ukraine	1	28/04/2031	UAA200711345	Yes, MPP and bilateral licenses
Viet Nam	2	28/04/2026	VN201300151	Yes, MPP and bilateral licenses

Dolutegravir + Lamivudine + Tenofovir

There are 34 jurisdictions with 92 active filings. The first date of expiration was 2017; the latest patent is estimated to expire in 2038.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Albania	1	24/01/2031	EP19151897	No
Algeria	2	24/01/2031	DZ120523	No
Armenia	3	28/04/2031	EA200702080	Yes, MPP and bilateral licenses
Azerbaijan	3	24/01/2031	EA201892277	No
Belarus	3	24/01/2031	EA201892277	No
Bosnia and Herzegovina	1	24/01/2031	EP19151897	No
Brazil	3	24/01/2031	BR112012018670	No

China	7	09/12/2029	CN200980149670	No
Colombia	2	28/04/2026	CO07115501A	No
Dominican Republic	1	18/07/2032	DO2012000205	No
Egypt	2	23/01/2031	EG2012001288	Yes, MPP and bilateral licenses
India	5	09/12/2029	IN1971/KOLNP/2011	Yes, MPP and bilateral licenses
Indonesia	4	24/01/2031	IDW00201203037	Yes, MPP and bilateral licenses
Kazakhstan	3	24/01/2031	EA201892277	No
Kyrgyz Republic	3	24/01/2031	EA202190473	Yes, MPP and bilateral licenses
Malaysia	2	24/01/2031	MY2012003346	No
Mexico	6	24/01/2031	MX2014014687	No
Moldova, Republic of	3	24/01/2031	EA201892277	Yes, MPP and bilateral licenses
Montenegro	1	24/01/2031	EP19151897	No
Morocco	1	28/04/2026	MA30388	Yes, MPP and bilateral licenses
Nigeria	1	28/04/2026	NG2007/12/473	Yes, MPP and bilateral licenses
North Macedonia	2	24/01/2031	EP19151897	
Philippines	3	26/11/2038	PH12018502489	Yes, MPP and bilateral licenses
Russian Federation	5	24/01/2031	EA201892277	No
Serbia	1	24/01/2031	EP19151897	No
South Africa	1	28/04/2026	ZA200708970	Yes, MPP and bilateral licenses
Tajikistan	3	24/01/2031	EA201892277	Yes, MPP and bilateral licenses
Thailand	1	24/01/2031	TH1201003753	No
Trinidad and Tobago	2	28/04/2026	TT200700254	No
Turkey	9	24/01/2031	EP19151897	No
Turkmenistan	3	24/01/2031	EA201892277	Yes, MPP and bilateral licenses
Ukraine	1	28/04/2031	UAA200711345	Yes, MPP and bilateral licenses
United Arab Emirates	1	24/01/2031	AE20120790	No

Viet Nam	3	24/08/2032	VN201202514	Yes, MPP and bilateral licenses
-----------------	---	------------	-------------	---------------------------------

Empagliflozin

There are 63 jurisdictions with 223 active filings. The first date of expiration is expected to occur in 2025; the latest patent is estimated to expire in 2034.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Albania	3	03/04/2034	EP14715274	No
Algeria	3	11/02/2030	DZ110606	No
Argentina	1	16/03/2025	ARP050101020	No
Armenia	2	15/08/2028	EA201000321	No
Azerbaijan	2	15/08/2028	EA201000321	No
Belarus	8	03/04/2034	EA201500996	No
Benin	2	07/11/2031	OA12013500809	No
Bosnia and Herzegovina	10	03/04/2034	EP18197967	No
Botswana	1	11/02/2030	AP/P/2011/005795	No
Brazil	5	11/02/2030	BRPI1013638	No
Burkina Faso	2	07/11/2031	OA12013500809	No
Cameroon	2	07/11/2031	OA12013500809	No
Central African Republic	2	07/11/2031	OA12013500809	No
Chad	2	07/11/2031	OA12013500809	No
Chile	7	03/04/2034	CL2015002941	No
China	5	03/04/2034	CN201811554457	No
Colombia	3	15/08/2028	CO10012795	No
Congo	2	07/11/2031	OA12013500809	No
Côte d'Ivoire	2	07/11/2031	OA12013500809	No
Ecuador	2	11/02/2030	ECSP11011275	No
Egypt	5	07/11/2031	EG2013693	No
Equatorial Guinea	2	07/11/2031	OA12013500809	No
Gabon	2	07/11/2031	OA12013500809	No

Georgia	2	07/11/2031	GE1311401	No
Guinea	2	07/11/2031	OA12013500809	No
Guinea-Bissau	2	07/11/2031	OA12013500809	No
India	5	11/02/2030	IN6157/DELNP/2011	No
Indonesia	4	11/02/2030	IDW00201103176	No
Kazakhstan	7	03/04/2034	EA201500997	No
Kenya	1	11/02/2030	AP/P/2011/005795	No
Kosovo	1	11/03/2025	KV2012-34	No
Kyrgyz Republic	1	15/08/2028	EA201000321	No
Malaysia	4	11/02/2030	MYPI2011003760	No
Mali	2	07/11/2031	OA12013500809	No
Mauritania	2	07/11/2031	OA12013500809	No
Mexico	8	03/04/2034	MX2015013948	No
Moldova, Republic of	2	15/08/2028	EA201000321	No
Montenegro	7	03/04/2034	EP14715274	No
Morocco	2	11/02/2030	MA34088	No
Mozambique	1	11/02/2030	AP/P/2011/005795	No
Namibia	1	11/02/2030	AP/P/2011/005795	No
Niger	2	07/11/2031	OA12013500809	No
Nigeria	2	07/11/2031	NG2013-300	No
North Macedonia	6	03/04/2034	EP14715274	No
Pakistan	2	16/08/2027	PK993-2008	No
Peru	4	14/08/2028	PE2008001382	No
Philippines	10	03/04/2034	PH12015502276	No
Russian Federation	8	03/04/2034	EA201500996	No
Senegal	2	07/11/2031	OA12013500809	No
Serbia	12	03/04/2034	EP14715274	No
South Africa	6	07/11/2031	ZA201302423	No
Tajikistan	2	15/08/2028	EA201000321	No
Tanzania	1	11/02/2030	AP/P/2011/005795	No
Thailand	4	11/02/2030	TH1101001519	No
Togo	2	07/11/2031	OA12013500809	No
Tunisia	3	29/04/2033	TN2013000187	No

Turkey	10	03/04/2034	EP14715274	No
Turkmenistan	2	15/08/2028	EA201000321	No
Ukraine	4	17/04/2031	UAA200713271	No
United Arab Emirates	4	07/11/2031	AE4912013	No
Uruguay	3	15/08/2028	UY31296	No
Venezuela	1	14/03/2025	VE2005-000467	No
Viet Nam	4	11/02/2030	VN1201102416	No

Empagliflozin Therapeutic Equivalent: Canagliflozin

The EML lists canagliflozin as a therapeutic alternative to empagliflozin. There are 44 jurisdictions with 158 active filings. The first date of expiration is expected to occur in 2027; the latest patent is estimated to expire in 2031.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Albania	4	11/05/2031	EP11721616	No
Argentina	4	11/05/2031	ARP110101625	No
Armenia	4	11/05/2031	EA201291217	No
Azerbaijan	4	11/05/2031	EA201291217	No
Belarus	4	11/05/2031	EA201291217	No
Bosnia and Herzegovina	4	11/05/2031	EP11721616	No
Brazil	5	11/05/2031	BR112012028857	No
Chile	3	11/05/2031	CL2012003162	No
China	7	11/05/2031	CN201810156110	No
Colombia	2	07/07/2030	CO12002313	No
Costa Rica	4	11/05/2031	CR20120626	No
Ecuador	3	11/05/2031	ECSP12012290	No
Egypt	2	11/05/2031	EGPCT/1875/2012	No
El Salvador	3	11/05/2031	SVE-4345/2012	No
Guatemala	3	11/05/2031	GT201200303	No
Honduras	3	11/05/2031	HN2012-2424	No
India	4	07/07/2030	IN639DEN2012	No
Indonesia	4	11/05/2031	IDW00201205102	No

Jordan	1	11/05/2031	JOP20110159	No
Kazakhstan	4	11/05/2031	EA201291217	No
Kyrgyz Republic	4	11/05/2031	EA201291217	No
Malaysia	4	11/05/2031	MYPI2012700923	No
Mexico	5	11/05/2031	MX2012013090	No
Moldova, Republic of	4	11/05/2031	EA201291217	No
Montenegro	5	11/05/2031	EP11721616	No
Nicaragua	3	11/05/2031	NI201200168	No
North Macedonia	4	11/05/2031	EP11721616	No
Pakistan	2	11/05/2031	PK2011/342	No
Panama	1	03/12/2027	PA8759401	No
Peru	2	11/05/2031	PE2012002148	No
Philippines	4	11/05/2031	PH1/2012/502216	No
Russian Federation	5	11/05/2031	EA201291217	No
Serbia	6	11/05/2031	EP11721616	No
South Africa	5	11/05/2031	ZA201209344	No
Sri Lanka	3	11/05/2031	LK16295	No
Tajikistan	4	11/05/2031	EA201291217	No
Thailand	3	11/05/2031	TH1201005877	No
Turkey	7	11/05/2031	EP11721616	No
Turkmenistan	4	11/05/2031	EA201291217	No
Ukraine	4	11/05/2031	UAA201214097	No
United Arab Emirates	1	11/05/2031	GC2011-18384	No
Uruguay	1	11/05/2031	UY33380	No
Venezuela	2	04/05/2031	VE2011-000632	No
Viet Nam	3	11/05/2031	VN1-2012-03367	No

Empagliflozin Therapeutic Equivalent: Dapagliflozin

The EML lists dapagliflozin as a therapeutic alternative to empagliflozin. There are 36 jurisdictions with 100 active filings. The first date of expiration is expected to occur in 2022; the latest patent is estimated to expire in 2032. Note: In general, we have not analyzed the applicability of patents that have been identified by our data sources as members of patent families relevant to drugs listed in the EML. However, this analysis excludes several later-expiring patents potentially relevant to dapagliflozin, as the EML listing is for “Oral hypoglycaemic agents” for diabetes, and the later-expiring patents apply to methods of use for indications not on the EML.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Albania	4	21/03/2028	EP08732695	No
Argentina	1	16/05/2023	ARP030101713	No
Armenia	2	21/06/2027	EA202091391	No
Azerbaijan	2	21/06/2027	EA201791254	No
Belarus	2	21/06/2032	EA201791254	No
Bosnia and Herzegovina	3	21/03/2028	EP12153939	No
Brazil	7	21/03/2028	BR122017015098	No
Chile	3	28/06/2027	CL2007001915	No
China	7	21/03/2028	CN201210201489	No
Colombia	1	15/05/2023	CO04115963	No
Egypt	1	20/06/2027	EG2008122077	No
Georgia	1	15/05/2023	GEAU2003008537	No
India	2	21/03/2028	IN6038/DELNP/2009	No
Indonesia	2	21/06/2027	IDW00200804202	No
Kazakhstan	6	21/06/2032	EA201791254	No
Kosovo	1	15/05/2023	KV195	No
Kyrgyz Republic	2	21/06/2027	EA202091391	No
Malaysia	2	21/06/2027	MYPI20085336	No
Mexico	6	21/03/2028	MX2011010219	No
Moldova, Republic of	2	21/06/2027	EA202091391	No
Montenegro	2	15/05/2023	MEP2008130	No
North Macedonia	4	21/03/2028	EP12153939	No
Pakistan	1	20/05/2022	PK0432/2003	No
Peru	1	20/05/2023	PE2003000491	No
Philippines	3	21/06/2027	PH12012500168	No
Russian Federation	11	21/08/2029	EA201791254	No
Serbia	6	21/03/2028	EP12153939	No
South Africa	2	21/06/2027	ZA200810475	No
Tajikistan	2	21/06/2027	EA201791254	No

Thailand	1	19/05/2023	TH0301001821	No
Turkey	4	21/03/2028	EP08732695	No
Turkmenistan	2	21/06/2027	EA201791254	No
Ukraine	2	21/06/2027	UAA200900606	No
Venezuela	1	20/05/2022	VE2003000775	No
Viet Nam	1	15/05/2023	VN1-2004-01327	No

Etonogestrel-Releasing Implant

There are 10 jurisdictions with 28 active filings. The first date of expiration is expected to occur in 2024; the latest patent is estimated to expire in 2026.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Argentina	4	19/01/2026	59069	No
Brazil	4	19/01/2026	PI0706472	No
China	4	19/01/2026	101370550	No
Ecuador	1	19/03/2024	SP066865	No
Egypt	1	19/03/2024	24359	No
Malaysia	1	19/03/2024	142649	No
Mexico	3	24/01/2025	2007008880	No
Peru	3	24/01/2025	20061216	No
South Africa	4	19/01/2026	200805243	No
Ukraine	3	24/01/2025	88674	No

Glecaprevir + Pibrentasvir

There are 44 jurisdictions with 303 active filings. The first date of expiration is expected to occur in 2030; the latest patent is estimated to expire in 2040.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Albania	17	12/02/2038	EP18156337	No
Argentina	4	02/03/2040	ARP200100565	No
Armenia	6	12/10/2036	EA201390538	No
Azerbaijan	6	24/06/2036	EA201890160	No

Belarus	7	18/07/2036	EA201890334	No
Bolivia (Plurinational State of)	4	12/10/2031	BO201100314F1	Yes, MPP license
Bosnia and Herzegovina	9	18/07/2036	EP16745584	No
Brazil	9	15/02/2038	BR102018002956	No
Chile	5	18/07/2036	CL2018000138	No
China	15	13/02/2038	CN201810149405	No
Colombia	4	24/06/2036	CO2017013305	No
Costa Rica	4	18/07/2036	CR20180088	No
Dominican Republic	6	18/07/2036	DO2018000024	No
Ecuador	6	18/07/2036	ECPI201808411	No
Egypt	4	17/07/2036	EG2018000084	Yes, MPP license
Guatemala	6	18/07/2036	GTA-2018-000025	No
India	4	24/06/2036	IN201817002543	No
Indonesia	4	18/07/2036	IDP00201801161	Yes, MPP license
Kazakhstan	7	18/07/2036	EA201890334	No
Kyrgyz Republic	6	24/06/2036	EA201890160	No
Malaysia	5	18/07/2036	MYPI2018700194	No
Mexico	16	18/07/2036	MX2018000746	No
Moldova, Republic of	4	18/07/2036	EP16745584	No
Mongolia	4	18/07/2036	MN6197	No
Montenegro	10	18/07/2036	EP16745584	No
Morocco	2	05/06/2035	EP15803592	Yes, MPP license
North Macedonia	16	12/02/2038	EP18156337	No
Pakistan	3	12/10/2031	PK2011000752	Yes, MPP license
Panama	4	18/07/2036	PA91954	No
Paraguay	3	10/04/2034	PY2017034231	No
Peru	4	18/07/2036	PE2018000084	No
Philippines	4	18/07/2036	PH12018500132	Yes, MPP license
Russian Federation	10	18/07/2036	EA201890334	No
Serbia	22	12/02/2038	EP18156337	No
South Africa	14	24/05/2039	ZA201903284	Yes, MPP license

Tajikistan	7	18/07/2036	EA201890334	No
Thailand	4	18/07/2036	TH1801000311	No
Turkey	16	12/02/2038	EP18156337	No
Turkmenistan	7	18/07/2036	EA201890334	Yes, MPP license
Ukraine	4	18/07/2036	UAa201801549	No
United Arab Emirates	3	12/10/2031	GC2011019503	No
Uruguay	2	12/10/2031	UY33667	No
Venezuela	2	11/10/2031	VE2011001332	Yes, MPP license
Viet Nam	4	18/07/2036	VN1201800634	No

HPV Vaccine

There are 55 jurisdictions with 75 active filings. The first date of expiration is expected to occur in 2023; the latest patent is estimated to expire in 2025.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Algeria	1	14/06/2025	DZP2007000025	No
Armenia	1	25/09/2023	EA11477	No
Azerbaijan	1	25/09/2023	EA11477	No
Belarus	1	25/09/2023	EA11477	No
Benin	1	25/09/2023	OA12787	No
Botswana	1	25/09/2023	AP1872	No
Brazil	4	14/06/2025	PI0512042	No
Burkina Faso	1	25/09/2023	OA12787	No
Cameroon	1	25/09/2023	OA12787	No
Central African Republic	1	25/09/2023	OA12787	No
Chad	1	25/09/2023	OA12787	No
China	4	11/10/2024	1942583	No
Comoros	1	25/09/2023	OA12787	No
Congo	1	25/09/2023	OA12787	No
Côte d'Ivoire	1	25/09/2023	OA12787	No
Equatorial Guinea	1	25/09/2023	OA12787	No

Eswatini	1	25/09/2023	AP1872	No
Gabon	1	25/09/2023	OA12787	No
Gambia	1	25/09/2023	AP1872	No
Ghana	1	25/09/2023	AP1872	No
Guinea	1	25/09/2023	OA12787	No
Guinea-Bissau	1	25/09/2023	OA12787	No
India	3	14/06/2025	3436/KOLNP/2006	No
Kazakhstan	1	25/09/2023	EA11477	No
Kenya	1	25/09/2023	AP1872	No
Kyrgyz Republic	1	25/09/2023	EA11477	No
Lesotho	1	25/09/2023	AP1872	No
Liberia	1	25/09/2023	AP1872	No
Malawi	1	25/09/2023	AP1872	No
Malaysia	3	11/10/2024	139500	No
Mali	1	25/09/2023	OA12787	No
Mauritania	1	25/09/2023	OA12787	No
Mexico	5	14/06/2025	PA/a/2006/014515	No
Morocco	1	14/06/2025	28692	No
Mozambique	1	25/09/2023	AP1872	No
Namibia	1	25/09/2023	AP1872	No
Niger	1	25/09/2023	OA12787	No
Philippines	1	25/09/2023	12004501460	No
Russian Federation	4	14/06/2025	2420313	No
Rwanda	1	25/09/2023	AP1872	No
Sao Tome & Principe	1	25/09/2023	AP1872	No
Senegal	1	25/09/2023	OA12787	No
Sierra Leone	1	25/09/2023	AP1872	No
Somalia	1	25/09/2023	AP1872	No
South Africa	4	11/10/2024	200603106	No
Sudan	1	25/09/2023	AP1872	No
Tajikistan	1	25/09/2023	EA11477	No
Tanzania	1	25/09/2023	AP1872	No
Togo	1	25/09/2023	OA12787	No

Turkmenistan	1	25/09/2023	EA11477	No
Uganda	1	25/09/2023	AP1872	No
Ukraine	1	25/09/2023	85536	No
Zambia	1	25/09/2023	AP1872	No
Zimbabwe	1	25/09/2023	AP1872	No

Ibrutinib

There are 26 jurisdictions with 169 active filings. The first date of is expected to occur in 2026; the latest patent is estimated to expire in 2035.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Argentina	4	03/03/2035	103832	No
Armenia	13	25/10/2033	201690745	No
Azerbaijan	13	25/10/2033	201690745	No
Belarus	13	25/10/2033	201690745	No
Brazil	6	03/03/2035	112017018931	No
Chile	4	04/06/2032	2014003306	No
China	13	03/03/2035	107427498	No
Colombia	1	04/06/2032	7240408	No
Costa Rica	1	04/06/2032	20140558	No
Dominican Republic	2	04/06/2032	P2014000274	No
Ecuador	2	04/06/2032	SP14033163	No
Guatemala	1	04/06/2032	201400281	No
Jordan	2	04/06/2032	3754	No
Kazakhstan	13	25/10/2033	201690745	No
Kyrgyz Republic	13	25/10/2033	201690745	No
Mexico	10	03/03/2035	2017011270	No
Morocco	3	03/03/2035	41643	No
Peru	2	04/06/2032	20150174	No
Philippines	4	25/10/2033	12016500768	No
Russian Federation	14	03/03/2035	2017133990	No
South Africa	5	03/06/2030	201209381	No

Tajikistan	13	25/10/2033	201690745	No
Tunisia	1	04/06/2032	2014000492	No
Turkmenistan	13	25/10/2033	201690745	No
Ukraine	2	04/06/2032	114421	No
Uruguay	1	04/06/2032	34848	No

Ledipasvir + Sofosbuvir

There are 87 jurisdictions with 554 active filings. The first date of expiration is expected to occur in 2028; the latest patent is estimated to expire in 2036.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Albania	15	30/01/2034	EP19203320	No
Argentina	5	31/01/2034	ARP140100352	No
Armenia	11	31/03/2036	EA201290993	Yes, bilateral license
Azerbaijan	11	30/01/2034	EA201490806	No
Bahamas	2	30/01/2034	BS2561	No
Belarus	11	30/01/2034	EA201490806	Yes, bilateral license
Benin	4	31/01/2034	OA1201500300	Yes, bilateral license
Bolivia (Plurinational State of)	1	28/11/2032	BO20120434	Yes, bilateral license
Bosnia and Herzegovina	14	30/01/2034	EP19203320	No
Botswana	6	30/01/2034	AP201508630	Yes, bilateral license
Brazil	8	30/01/2034	BR112014011938	No
Burkina Faso	4	31/01/2034	OA1201500300	Yes, bilateral license
Cameroon	4	31/01/2034	OA1201500300	Yes, bilateral license
Central African Republic	4	31/01/2034	OA1201500300	Yes, bilateral license
Chad	4	31/01/2034	OA1201500300	Yes, bilateral license
Chile	8	31/07/2035	CL2015002164	No
China	20	30/01/2034	CN201610111865	No
Colombia	5	30/01/2034	CO15203177	No
Comoros	1	31/01/2034	OA1201500300	Yes, bilateral license
Congo	4	31/01/2034	OA1201500300	Yes, bilateral license

Costa Rica	2	31/08/2035	CR20150453	No
Côte d'Ivoire	4	31/01/2034	OA1201500300	Yes, bilateral license
Ecuador	3	30/01/2034	ECPI201537311	No
Egypt	5	29/01/2034	EG/P/2014/790	Yes, bilateral license
El Salvador	3	30/01/2034	SVE-5026-2015	Yes, bilateral license
Equatorial Guinea	4	31/01/2034	OA1201500300	Yes, bilateral license
Eswatini	6	30/01/2034	AP201508630	Yes, bilateral license
Ethiopia	2	12/05/2030	ET20170243	Yes, bilateral license
Fiji	1	26/03/2028	FJ1237	Yes, bilateral license
Gabon	4	31/01/2034	OA1201500300	Yes, bilateral license
Gambia	8	30/01/2034	AP201508630	Yes, bilateral license
Ghana	6	30/01/2034	AP201508630	Yes, bilateral license
Guinea	4	31/01/2034	OA1201500300	Yes, bilateral license
Guinea-Bissau	4	31/01/2034	OA1201500300	Yes, bilateral license
Guyana	1	26/03/2028	GY1665	Yes, bilateral license
India	8	30/01/2034	IN3953/DELNP/2014	Yes, bilateral license
Indonesia	8	30/01/2034	IDP00201504713	Yes, bilateral license
Kazakhstan	11	30/01/2034	EA201490806	Yes, bilateral license
Kenya	6	30/01/2034	AP201508630	Yes, bilateral license
Kiribati	2	12/05/2030	KI2017016	Yes, bilateral license
Kyrgyz Republic	11	30/01/2034	EA201490806	Yes, bilateral license
Lesotho	6	30/01/2034	AP201508630	Yes, bilateral license
Liberia	6	30/01/2034	AP201508630	Yes, bilateral license
Malawi	6	30/01/2034	AP201508630	Yes, bilateral license
Malaysia	7	31/01/2034	MYPI2015001926	Yes, bilateral license
Mali	4	31/01/2034	OA1201500300	Yes, bilateral license
Mauritania	4	31/01/2034	OA1201500300	Yes, bilateral license
Mexico	18	30/01/2034	MX2014005955	No
Moldova, Republic of	9	27/11/2032	MD20140058	No
Montenegro	19	30/01/2034	EP19203320	No
Morocco	1	14/09/2032	MA36906	Yes, bilateral license
Mozambique	6	30/01/2034	AP201508630	Yes, bilateral license
Namibia	6	30/01/2034	AP201508630	Yes, bilateral license

Nauru	1	12/05/2030	NR2430014	Yes, bilateral license
Nepal	2	12/05/2030	NP41	Yes, bilateral license
Niger	4	31/01/2034	OA1201500300	Yes, bilateral license
North Macedonia	17	30/01/2034	EP14704502	No
Pakistan	4	31/01/2034	PK0054/2014	Yes, bilateral license
Panama	3	31/07/2035	PA90777	No
Paraguay	2	28/11/2032	PY2012056476	Yes, bilateral license
Peru	6	30/01/2034	PE2015001594	No
Philippines	9	30/01/2034	PH12015501710	Yes, bilateral license
Russian Federation	14	19/02/2035	EA201490806	No
Rwanda	3	30/01/2034	AP201508630	Yes, bilateral license
Saint Lucia	1	26/03/2028	LC201610	No
Senegal	4	31/01/2034	OA1201500300	Yes, bilateral license
Serbia	18	30/01/2034	EP19203320	No
Seychelles	2	12/05/2030	SC2430014	Yes, bilateral license
Sierra Leone	6	30/01/2034	AP201508630	Yes, bilateral license
Solomon Islands	1	26/03/2028	SB37/384	Yes, bilateral license
South Africa	14	31/01/2034	ZA201505718	Yes, bilateral license
Sudan	6	30/01/2034	AP201508630	Yes, bilateral license
Tajikistan	11	30/01/2034	EA201490806	Yes, bilateral license
Tanzania	6	30/01/2034	AP201508630	Yes, bilateral license
Thailand	7	27/11/2032	TH1401002830	Yes, bilateral license
Togo	4	31/01/2034	OA1201500300	Yes, bilateral license
Turkey	22	30/01/2034	EP19203320	No
Turkmenistan	11	30/01/2034	EA201490806	Yes, bilateral license
Tuvalu	1	12/05/2030	TVP2430014	Yes, bilateral license
Uganda	5	30/01/2034	AP201508630	Yes, bilateral license
Ukraine	7	30/01/2034	UAA201508402	Yes, bilateral license
United Arab Emirates	5	30/01/2034	GC201426346	No
Uruguay	1	28/11/2032	UY34474	No
Venezuela	4	31/01/2034	VE92-2014	No
Viet Nam	4	31/01/2034	VN1201502805	Yes, bilateral license
Zambia	6	30/01/2034	AP201508630	Yes, bilateral license

Zimbabwe	6	30/01/2034	AP201508630	Yes, bilateral license
----------	---	------------	-------------	------------------------

Levonorgestrel-Releasing Intrauterine System

There are 6 jurisdictions with 13 active filings. The first date of expiration is expected to occur in 2028; the latest patent is estimated to expire in 2028.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Argentina	1	17/09/2028	75548	No
Brazil	2	17/09/2028	PI0919228	No
China	2	17/09/2028	102159162	No
Mexico	2	17/09/2028	2011002671	No
Russian Federation	4	17/09/2028	2011115057	No
South Africa	2	17/09/2028	201100900	No

Lopinavir + Ritonavir

There are 14 jurisdictions with 14 active filings. The first date of expiration was 2012; the latest patent is estimated to expire in 2029.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Belize	2	21/02/2026	BZ481.07	Commitment to not enforce
Ecuador	3	23/08/2024	ECSP066397	Commitment to not enforce
Guatemala	2	05/07/2026	GT200600295	Commitment to not enforce
Mexico	4	23/08/2024	MXPA06002346	Commitment to not enforce
Montenegro	2	23/08/2024	MEP2008176	Commitment to not enforce
Nicaragua	4	21/02/2026	NI200700219	Commitment to not enforce
Panama	2	23/02/2026	PA8664801	Commitment to not enforce
Philippines	6	21/02/2026	PH12007501802	Commitment to not enforce

South Africa	8	21/02/2026	ZA200707022	Commitment to not enforce
Sri Lanka	4	21/02/2026	LK14598	Commitment to not enforce
United Arab Emirates	2	22/02/2026	GC200605867	Commitment to not enforce
Uruguay	4	14/09/2029	UY32116	Commitment to not enforce
Venezuela	2	22/02/2026	VE2006000342	Commitment to not enforce
Viet Nam	4	21/02/2026	VN1200701909	Commitment to not enforce

Meropenem + Vaborbactam

There are 17 jurisdictions with 25 active filings. The first date of expiration is expected to occur in 2023; the latest patent is estimated to expire in 2031.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Albania	2	08/08/2031	EP18183968	No
Bosnia and Herzegovina	1	08/08/2031	EP20156442	No
Brazil	1	08/08/2031	BR112013003045	No
Chile	1	08/08/2031	CL2013000399	No
China	1	08/08/2031	CN201180046975	No
India	1	08/08/2031	IN1146/DELNP/2013	No
Lao People's Democratic Republic (the)	1	08/08/2031	LAPT234	No
Malaysia	1	08/11/2023	MY2013000386	No
Mexico	1	08/08/2031	MX2013001517	No
Montenegro	1	08/08/2031	EP20156442	No
North Macedonia	3	08/08/2031	EP11816882	No
Russian Federation	1	08/08/2031	RU2013104951	No
Serbia	3	08/08/2031	EP20156442	No
South Africa	1	08/08/2031	ZA201301014	No
Thailand	1	08/08/2023	TH1301000670	No

Turkey	4	08/08/2031	EP20156442	No
Viet Nam	1	08/08/2023	VN1201300725	No

Nilotinib

There are 47 jurisdictions with 148 active filings. The first date of expiration is expected to occur in 2023; the latest patent is estimated to expire in 2032.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Albania	6	17/11/2030	EP10781781	No
Algeria	3	17/11/2030	DZ120382	No
Argentina	1	03/07/2023	ARP030102415	No
Barbados	1	18/07/2026	BB200101377	No
Belize	1	18/07/2026	BZ497.07	No
Bolivia (Plurinational State of)	2	20/07/2026	BOSP260180	No
Bosnia and Herzegovina	6	17/11/2030	EP10781781	No
Brazil	4	25/09/2027	BRPI0719438	No
Chile	3	26/09/2027	CL2007002766	No
China	4	17/11/2030	CN201080051819	No
Colombia	2	27/09/2027	CO13281357	No
Cuba	2	18/07/2026	CU20080006	No
Ecuador	1	04/07/2023	ECSP055525	No
Egypt	2	18/07/2026	EG2008010079	No
Guatemala	3	17/11/2030	GT201200150	No
India	2	18/07/2026	IN9925/DELNP/2007	No
Indonesia	3	17/11/2030	IDW00201201854	No
Iraq	3	02/11/2030	IQ328/2010	No
Jordan	5	14/11/2030	JOP20100396	No
Korea, DPR of	1	18/07/2026	KP07-4692	No
Kosovo	1	18/07/2026	KV20080215	No
Lebanon	3	11/11/2030	LB201009197	No
Libya	1	18/07/2026	LY200803555	No
Malaysia	5	17/11/2030	MYPI2012001993	No

Mexico	5	17/11/2030	MX2012005694	No
Montenegro	2	17/11/2030	MEP8916	No
Morocco	4	17/11/2030	MA34855	No
Nicaragua	1	18/07/2026	NI200800017	No
North Macedonia	6	17/11/2030	EP10781781	No
Pakistan	3	15/11/2030	PK20100967	No
Panama	2	20/07/2026	PA8687301	No
Paraguay	2	20/07/2026	PY2006020442	No
Peru	3	25/09/2027	PE2007001294	No
Philippines	5	17/11/2030	PH12012500965	No
Russian Federation	10	17/11/2030	RU2012124811	No
Serbia	8	17/11/2030	RSP20160303	No
South Africa	5	17/11/2030	ZA201203328	No
Sri Lanka	1	18/07/2026	LK14792	No
Syrian Arab Republic	1	18/07/2026	SY2006007763	No
Thailand	3	17/07/2026	TH0601003348	No
Trinidad and Tobago	1	18/07/2026	TT200700314	No
Tunisia	5	07/05/2032	TNSN20120206	No
Turkey	7	17/11/2030	EP10781781	No
United Arab Emirates	3	10/11/2030	GC2010017112	No
Uzbekistan	1	18/07/2026	UZ20080049	No
Venezuela	3	16/11/2030	VE2010001791	No
Viet Nam	2	18/07/2026	VN1200800388	No

Nivolumab

There are 7 jurisdictions with 15 active filings. The first date of expiration was 2017; the latest patent is estimated to expire in 2037.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Brazil	1	5/2/26	BRPI0610235	No
China	4	5/2/26	CN200680023860	No
India	2	5/2/26	IN201948035076	No

Mexico	1	5/2/26	MX2007013978	No
Russian Federation	4	5/2/26	RU2007145419	No
South Africa	1	5/2/26	ZA200709631	No
Turkey	2	5/2/26	EP09013687	No

Nivolumab Therapeutic Alternative: Pembrolizumab

The EML lists pembrolizumab as a therapeutic alternative to nivolumab. There are 25 jurisdictions with 41 active filings. The first date of expiration is expected to occur in 2028; the latest patent is estimated to expire in 2028.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Albania	3	13/06/2028	EP16205393	No
Anguilla	1	13/06/2028	AI/A/2014/00167	No
Bosnia and Herzegovina	3	13/06/2028	EP08768485	No
Brazil	2	13/06/2028	BRPI0812913	No
China	2	13/06/2028	CN200880103544	No
Fiji	1	13/06/2028	FJ1203	No
Grenada	1	13/06/2028	GD1OF2015	No
Guyana	1	13/06/2028	GY1635	No
India	2	13/06/2028	IN7435/CHENP/2009	No
Indonesia	1	13/06/2028	IDW00200903590	No
Kiribati	1	13/06/2028	KI2170959	No
Mexico	2	13/06/2028	MX2009014199	No
Montenegro	1	13/06/2028	MEP54513	No
North Macedonia	3	13/06/2028	EP12170052	No
Philippines	2	13/06/2028	PH12015501524	No
Saint Lucia	1	13/06/2028	LCPT01/2005	No
Serbia	4	13/06/2028	EP16205393	No
Seychelles	1	13/06/2028	SC2170959	No
Sierra Leone	1	13/06/2028	SL2170959	No
Solomon Islands	1	13/06/2028	SBJ37/366	No
South Africa	1	13/06/2028	ZA201000135	No

Turkey	3	13/06/2028	EP16205393	No
Turks and Caicos Islands	1	13/06/2028	TC10208	No
Tuvalu	1	13/06/2028	TVP2170959	No
Virgin Islands (British)	1	13/06/2028	VG2170959	No

Ombitasvir + Paritaprevir + Ritonavir

There are 44 jurisdictions with 152 active filings. The first date of expiration was 2012; the latest patent is estimated to expire in 2037.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Albania	4	09/06/2031	EP11727080	No
Argentina	3	10/06/2030	ARP100102058	No
Armenia	3	10/06/2030	EA201400115	No
Azerbaijan	2	04/09/2030	EA201170401	No
Belarus	3	04/04/2031	EA201170401	No
Bolivia (Plurinational State of)	2	10/06/2031	BO201100171	No
Brazil	3	26/05/2031	BR112012030014	No
Chile	5	07/08/2033	CL2013002299	No
China	4	09/06/2031	CN201180039382	No
Colombia	3	09/06/2031	CO12234723	No
Costa Rica	1	10/09/2029	CR20110123	No
Dominican Republic	3	29/03/2031	DO2011000087	No
Ecuador	6	29/09/2037	ECPI201764986	No
Egypt	1	09/09/2029	EG20110365	No
Guatemala	3	09/06/2031	GT201200332	No
India	1	10/09/2029	IN7222/DELNP/2009	No
Indonesia	1	10/09/2029	IDW00201100889	No
Kazakhstan	3	25/11/2030	EA201170401	No
Kyrgyz Republic	3	10/06/2030	EA201400115	No
Malaysia	2	10/06/2030	MYPI2011001412	No
Mexico	6	09/06/2031	MX2012014384	No

Moldova, Republic of	3	27/07/2031	EA201170401	No
Mongolia	2	09/06/2031	MN201104998	No
Montenegro	3	09/06/2031	MEP15515	No
Nicaragua	1	23/08/2024	NI200600051	No
North Macedonia	9	09/06/2031	EP11727080	No
Pakistan	3	09/06/2031	PK20110424	No
Panama	3	10/06/2031	PA89318	No
Paraguay	1	09/06/2031	PY2011023397	No
Peru	4	09/06/2031	PE2012002294	No
Philippines	4	09/02/2035	PH12015500289	No
Russian Federation	4	09/06/2031	EA201291394	No
Serbia	9	09/06/2031	RSP20181205	No
South Africa	9	09/06/2031	ZA201300112	No
Sri Lanka	1	23/08/2024	LK13996	No
Tajikistan	1	10/06/2030	EA201400115	No
Thailand	1	11/09/2029	TH0901004135	No
Turkey	11	09/06/2031	EP11727080	No
Turkmenistan	2	10/06/2030	EA201400115	No
Ukraine	6	09/06/2031	UAA201300334	No
United Arab Emirates	5	12/10/2037	GC201134108	No
Uruguay	2	10/06/2030	UY32699	No
Venezuela	3	09/06/2031	VE2011000762	No

Plazomicin

There are 14 jurisdictions with 16 active filings. The first date of expiration is expected to occur in 2028; the latest patent is expected to expire in 2028.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Armenia	1	21/11/2028	EA201070597	No
Azerbaijan	1	21/11/2028	EA201070597	No
Belarus	1	21/11/2028	EA201070597	No
Brazil	1	21/11/2028	BRPI0819319	No
China	2	21/11/2028	CN201310142186	No

India	1	21/11/2028	IN4165/DELNP/2010	No
Kazakhstan	1	21/11/2028	EA201070597	No
Kyrgyz Republic	1	21/11/2028	EA201070597	No
Mexico	1	21/11/2028	MX2010005632	No
Moldova, Republic of	1	21/11/2028	EA201070597	No
Russian Federation	1	21/11/2028	EA201070597	No
Tajikistan	1	21/11/2028	EA201070597	No
Turkey	2	21/11/2028	EP16195678	No
Turkmenistan	1	21/11/2028	EA201070597	No

Raltegravir

There are 52 jurisdictions with 81 active filings. The first date of expiration is expected to occur in 2022; the latest patent is estimated to expire in 2030.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Albania	5	20/10/2030	EP10827338	No
Algeria	2	1/12/2025	DZ070325	No
Anguilla	1	30/7/2026	AI/A/2006/00019	No
Barbados	1	1/12/2025	BB200101317	No
Belarus	2	1/12/2025	EA200701204	No
Belize	1	1/12/2025	BZ20070468	No
Bosnia and Herzegovina	1	1/12/2025	BAE00794	No
Brazil	3	20/10/2030	BR112012009857	No
Chile	2	1/12/2025	CL200503144	No
China	5	20/10/2030	CN201610500807	No
Colombia	2	1/12/2025	CO07055540	No
Dominica	1	21/10/2022	DM/5/2006	No
Ecuador	1	20/10/2022	ECSP045074	No
Egypt	1	1/12/2025	EG2007000534	No
Fiji	1	5/7/2026	FJ960	No
Gambia	1	20/10/2022	GM1441735	No
Georgia	2	1/12/2025	GEAP2005010157	No

India	2	20/10/2030	IN3377DEN2012	No
Indonesia	2	1/12/2025	ID200701697	No
Kiribati	1	20/10/2022	KI144735	No
Lebanon	1	29/11/2025	LB05007367	No
Malaysia	2	20/10/2030	MYPI2012001823	No
Mexico	4	20/10/2030	MX2012004903	No
Mongolia	1	1/12/2027	MN3980	No
Montenegro	2	1/12/2025	MEP2112	No
Morocco	1	1/12/2025	MA30041	No
Nicaragua	1	1/12/2025	NI200700138	No
Pakistan	1	30/11/2025	PK200501139	No
Philippines	2	1/12/2025	PH12007501118	No
Russian Federation	1	20/10/2030	RU2012121857	No
Saint Lucia	1	20/10/2022	LCPT0003/2006	No
Saint Vincent and the Grenadines	1	2/07/2026	VC31	No
Serbia	3	2/12/2025	RSP20120021	No
Seychelles	1	20/10/2022	SC1441735	No
Sierra Leone	1	20/10/2022	SL021606	No
Solomon Islands	1	29/06/2026	SB37/213	No
South Africa	4	20/10/2030	ZA201203012	No
Thailand	1	28/12/2025	TH0501005605	No
Trinidad and Tobago	1	1/12/2025	TT200700120	No
Tunisia	1	31/05/2027	TNSN07215	No
Turkey	2	1/12/2025	EP12198385	No
Turks and Caicos Islands	1	15/06/2026	TC10057	No
Tuvalu	1	20/10/2022	TVP1441735	No
Ukraine	2	1/12/2025	UAA200707372	No
United Arab Emirates	1	29/11/2025	GC5453	No
Uzbekistan	1	20/10/2022	UZ20040189	No
Vanuatu	1	20/10/2022	VU22043	No
Venezuela	1	29/11/2025	VE2005002432	No

Viet Nam	2	1/12/2025	VN1200701323	No
Virgin Islands (British)	1	23/07/2026	VG248/10/2006	No

Ritonavir

There are 14 jurisdictions with 24 active filings. The first date of expiration was 2012; the latest patent is estimated to expire in 2029.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Belize	1	21/02/2026	BZ481.07	Commitment to not enforce
Ecuador	1	23/08/2024	ECSP066397	Commitment to not enforce
Guatemala	1	05/07/2026	GT200600295	Commitment to not enforce
Mexico	2	23/08/2024	MXPA06002346	Commitment to not enforce
Montenegro	1	23/08/2024	MEP2008176	Commitment to not enforce
Nicaragua	2	21/02/2026	NI200700219	Commitment to not enforce
Panama	1	23/02/2026	PA8664801	Commitment to not enforce
Philippines	3	21/02/2026	PH12012501811	Commitment to not enforce
South Africa	4	21/02/2026	ZA200707022	Commitment to not enforce
Sri Lanka	2	21/02/2026	LK14598	Commitment to not enforce
United Arab Emirates	1	22/02/2026	GC200605867	Commitment to not enforce
Uruguay	2	14/09/2029	UY32116	Commitment to not enforce
Venezuela	1	22/02/2026	VE2006000342	Commitment to not enforce
Viet Nam	2	21/02/2026	VN1200701909	Commitment to not enforce

Rituximab

There are 2 jurisdictions with 2 active filings for the indications listed on the EML. The first date of expiration occurred in earlier years; the latest patent is estimated to expire in 2023.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Malaysia	1	21/07/2023	MYPI20003637	No
Philippines	1	21/07/2022	PH11990347257	No

Sofosbuvir

There are 80 jurisdictions with 264 active filings. The first date of expiration is expected to occur in 2024; the latest patent is estimated to expire in 2036.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Albania	8	27/11/2032	EP20176183	No
Argentina	4	26/03/2028	AR120100340	No
Armenia	5	31/03/2036	EA201290993	Yes, bilateral license
Azerbaijan	5	27/11/2032	EA201490903	No
Belarus	5	27/11/2032	EA201490903	Yes, bilateral license
Benin	2	27/11/2032	OA1201400229	Yes, bilateral license
Bolivia	1	27/11/2032	BO20120434	Yes, bilateral license
Bosnia and Herzegovina	7	27/11/2032	EP12795307	No
Botswana	3	27/11/2032	AP201407699	Yes, bilateral license
Brazil	3	21/04/2024	BR122018015050	No
Burkina Faso	2	27/11/2032	OA1201400229	Yes, bilateral license
Cameroon	2	27/11/2032	OA1201400229	Yes, bilateral license
Central African Republic	2	27/11/2032	OA1201400229	Yes, bilateral license
Chad	2	27/11/2032	OA1201400229	Yes, bilateral license
Chile	5	27/11/2032	CL2014001397	No
China	11	27/11/2032	CN201280058114	No
Colombia	2	26/03/2028	CO09120744	No
Congo	2	27/11/2032	OA1201400229	Yes, bilateral license

Côte d'Ivoire	2	27/11/2032	OA1201400229	Yes, bilateral license
Ecuador	1	27/11/2032	ECSP14005678	No
Egypt	2	30/03/2031	EG2012091659D	Yes, bilateral license
El Salvador	2	27/11/2032	SV2014004722	Yes, bilateral license
Equatorial Guinea	2	27/11/2032	OA1201400229	Yes, bilateral license
Eswatini	2	27/11/2032	AP201407699	Yes, bilateral license
Ethiopia	1	25/03/2028	ET20170238	Yes, bilateral license
Fiji	1	26/03/2028	FJ1237	Yes, bilateral license
Gabon	2	27/11/2032	OA1201400229	Yes, bilateral license
Gambia	3	27/11/2032	AP201407699	Yes, bilateral license
Ghana	2	27/11/2032	AP201407699	Yes, bilateral license
Guinea	2	27/11/2032	OA1201400229	Yes, bilateral license
Guinea-Bissau	2	27/11/2032	OA1201400229	Yes, bilateral license
Guyana	1	26/03/2028	GY1665	Yes, bilateral license
India	3	20/05/2030	IN4972/KOLNP/2011	Yes, bilateral license
Indonesia	4	27/11/2032	ID00201403478	Yes, bilateral license
Kazakhstan	5	27/11/2032	EA201490903	Yes, bilateral license
Kenya	2	27/11/2032	AP201407699	Yes, bilateral license
Kiribati	1	25/03/2028	KI2017014	Yes, bilateral license
Kyrgyz Republic	5	27/11/2032	EA201490903	Yes, bilateral license
Lesotho	2	27/11/2032	AP201407699	Yes, bilateral license
Liberia	2	27/11/2032	AP201407699	Yes, bilateral license
Malawi	2	27/11/2032	AP201407699	Yes, bilateral license
Malaysia	6	27/11/2032	MYPI2014001520	Yes, bilateral license
Mali	2	27/11/2032	OA1201400229	Yes, bilateral license
Mauritania	2	27/11/2032	OA1201400229	Yes, bilateral license
Mexico	7	27/11/2032	MX2014006373	No
Moldova, Republic of	5	27/11/2032	MD20140058	No
Montenegro	8	27/11/2032	EP12795307	No
Mozambique	2	27/11/2032	AP201407699	Yes, bilateral license
Namibia	2	27/11/2032	AP201407699	Yes, bilateral license
Nepal	1	25/03/2028	NP14	Yes, bilateral license
Niger	2	27/11/2032	OA1201400229	Yes, bilateral license

North Macedonia	9	27/11/2032	EP12795307	No
Pakistan	3	27/11/2032	PK20120803	Yes, bilateral license
Panama	1	20/05/2030	PA2010088758	No
Paraguay	1	27/11/2032	PY2012056476	Yes, bilateral license
Peru	2	27/11/2032	PE2014000749	No
Philippines	7	27/11/2032	PH12014501133	Yes, bilateral license
Russian Federation	8	08/08/2034	EA201290993	No
Rwanda	1	27/11/2032	AP201407699	Yes, bilateral license
Saint Lucia	1	26/03/2028	LC201610	No
Senegal	2	27/11/2032	OA1201400229	Yes, bilateral license
Serbia	7	27/11/2032	EP20176183	No
Seychelles	1	25/03/2028	SC2203462	Yes, bilateral license
Sierra Leone	3	27/11/2032	AP201407699	Yes, bilateral license
Solomon Islands	1	26/03/2028	SB37/384	Yes, bilateral license
South Africa	9	27/11/2032	ZA201404061	Yes, bilateral license
Sudan	2	27/11/2032	AP201407699	Yes, bilateral license
Tajikistan	5	27/11/2032	EA201490903	Yes, bilateral license
Tanzania	2	27/11/2032	AP201407699	Yes, bilateral license
Thailand	5	27/11/2032	TH1401002830	Yes, bilateral license
Togo	2	27/11/2032	OA1201400229	Yes, bilateral license
Turkey	13	27/11/2032	EP20176183	No
Turkmenistan	5	27/11/2032	EA201490903	Yes, bilateral license
Uganda	2	27/11/2032	AP201407699	Yes, bilateral license
Ukraine	3	27/11/2032	UAA201405757	Yes, bilateral license
United Arab Emirates	3	27/11/2032	GCP2012022917	No
Uruguay	1	27/11/2032	UY34474	No
Venezuela	3	27/11/2032	VE2012001526	No
Viet Nam	1	27/11/2032	VN1201401861	Yes, bilateral license
Zambia	2	27/11/2032	AP201407699	Yes, bilateral license
Zimbabwe	2	27/11/2032	AP201407699	Yes, bilateral license

Sofosbuvir + Velpatasvir

There are 83 jurisdictions with 406 active filings. The first date of expiration is expected to occur in 2024; the latest patent is estimated to expire in 2037.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Albania	13	30/01/2034	EP19211345	No
Argentina	5	16/11/2031	ARP110104276	No
Armenia	9	16/11/2037	EA201390576	Yes, bilateral license
Azerbaijan	9	27/11/2032	EA201490903	No
Belarus	9	27/11/2032	EA201490903	Yes, bilateral license
Benin	3	27/11/2032	OA1201400229	Yes, bilateral license
Bolivia (Plurinational State of)	1	28/11/2032	BO20120434	Yes, bilateral license
Bosnia and Herzegovina	13	30/01/2034	EP19211345	No
Botswana	3	27/11/2032	AP201407699	Yes, bilateral license
Brazil	4	16/11/2032	BR112013012091	No
Burkina Faso	3	27/11/2032	OA1201400229	Yes, bilateral license
Cameroon	3	27/11/2032	OA1201400229	Yes, bilateral license
Central African Republic	3	27/11/2032	OA1201400229	Yes, bilateral license
Chad	3	27/11/2032	OA1201400229	Yes, bilateral license
Chile	6	27/11/2032	CL2014001397	No
China	14	30/01/2034	CN201480047195	No
Colombia	3	16/11/2032	CO13122291	No
Congo	3	27/11/2032	OA1201400229	Yes, bilateral license
Costa Rica	1	16/11/2032	CR20130231	No
Côte d'Ivoire	3	27/11/2032	OA1201400229	Yes, bilateral license
Ecuador	3	27/11/2032	ECPI201405678	No
Egypt	3	27/11/2032	EG2014000864	Yes, bilateral license
El Salvador	4	27/11/2032	SV2014004722	Yes, bilateral license
Equatorial Guinea	3	27/11/2032	OA1201400229	Yes, bilateral license
Eswatini	3	27/11/2032	AP201407699	Yes, bilateral license
Ethiopia	1	26/03/2028	ET20170238	Yes, bilateral license
Fiji	1	26/03/2028	FJ1237	Yes, bilateral license
Gabon	3	27/11/2032	OA1201400229	Yes, bilateral license

Gambia	4	27/11/2032	AP201407699	Yes, bilateral license
Ghana	3	27/11/2032	AP201407699	Yes, bilateral license
Guinea	3	27/11/2032	OA1201400229	Yes, bilateral license
Guinea-Bissau	3	27/11/2032	OA1201400229	Yes, bilateral license
Guyana	1	26/03/2028	GY1665	Yes, bilateral license
India	5	16/11/2032	IN4351/DELNP/2013	Yes, bilateral license
Indonesia	5	27/11/2032	ID00201403478	Yes, bilateral license
Kazakhstan	9	27/11/2032	EA201490903	Yes, bilateral license
Kenya	3	27/11/2032	AP201407699	Yes, bilateral license
Kiribati	1	26/03/2028	KI2017014	Yes, bilateral license
Kyrgyz Republic	9	27/11/2032	EA201490903	Yes, bilateral license
Lesotho	3	27/11/2032	AP201407699	Yes, bilateral license
Liberia	3	27/11/2032	AP201407699	Yes, bilateral license
Malawi	3	27/11/2032	AP201407699	Yes, bilateral license
Malaysia	7	27/11/2032	MYPI2014001520	Yes, bilateral license
Mali	3	27/11/2032	OA1201400229	Yes, bilateral license
Mauritania	3	27/11/2032	OA1201400229	Yes, bilateral license
Mexico	10	27/11/2032	MX2014006373	No
Moldova, Republic of	7	27/11/2032	MD20140058	No
Montenegro	15	30/01/2034	EP14704501	No
Morocco	1	16/11/2032	MA36000	Yes, bilateral license
Mozambique	3	27/11/2032	AP201407699	Yes, bilateral license
Namibia	3	27/11/2032	AP201407699	Yes, bilateral license
Nepal	1	26/03/2028	NP14	Yes, bilateral license
Niger	3	27/11/2032	OA1201400229	Yes, bilateral license
North Macedonia	15	30/01/2034	EP14704501	No
Pakistan	3	28/11/2032	PK20120803	Yes, bilateral license
Panama	2	16/11/2032	PA90000-01	No
Paraguay	1	28/11/2032	PY2012056476	Yes, bilateral license
Peru	4	27/11/2032	PE2014000749	No
Philippines	9	27/11/2032	PH12014501133	Yes, bilateral license
Russian Federation	12	08/08/2034	EA201290993	No
Rwanda	2	27/11/2032	AP201407699	Yes, bilateral license

Saint Lucia	1	26/03/2028	LC201610	No
Senegal	3	27/11/2032	OA1201400229	Yes, bilateral license
Serbia	15	30/01/2034	EP14704501	No
Seychelles	1	26/03/2028	SC2203462	Yes, bilateral license
Sierra Leone	3	27/11/2032	AP201407699	Yes, bilateral license
Solomon Islands	1	26/03/2028	SB37/384	Yes, bilateral license
South Africa	13	27/11/2032	ZA201404061	Yes, bilateral license
Sudan	3	27/11/2032	AP201407699	Yes, bilateral license
Tajikistan	9	27/11/2032	EA201490903	Yes, bilateral license
Tanzania	3	27/11/2032	AP201407699	Yes, bilateral license
Thailand	6	27/11/2032	TH1401002830	Yes, bilateral license
Togo	3	27/11/2032	OA1201400229	Yes, bilateral license
Turkey	20	30/01/2034	EP14704501	No
Turkmenistan	9	27/11/2032	EA201490903	Yes, bilateral license
Uganda	3	27/11/2032	AP201407699	Yes, bilateral license
Ukraine	6	27/11/2032	UAA201405757	Yes, bilateral license
United Arab Emirates	4	28/11/2032	GCP2012022917	No
Uruguay	1	28/11/2032	UY34474	No
Venezuela	3	28/11/2032	VE2012001526	No
Viet Nam	2	27/11/2032	VN1201401861	Yes, bilateral license
Zambia	3	27/11/2032	AP201407699	Yes, bilateral license
Zimbabwe	3	27/11/2032	AP201407699	Yes, bilateral license

Telmisartan + Hydrochlorothiazide

Relevant patents in several jurisdictions were estimated to expire in January 2022, as this paper was going to press. They were therefore excluded for purposes of this analysis, and there are no remaining relevant patents.

Thalidomide

There are 4 jurisdictions with 8 total active filings. The first date of expiration was 2020; the latest patent is estimated to expire in 2022.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Brazil	2	2022-11-14	0316240	No

China	3	2022-11-14	101816626	No
Mexico	2	2022-11-14	PA05005162	No
South Africa	1	2022-11-14	200503927	No

Tiotropium

There are 29 jurisdictions with 74 active filings. The first date of expiration was 2010; the latest patent is estimated to expire in 2026. Note: In general, we have not analyzed the applicability of patents that have been identified by our data sources as members of patent families relevant to drugs listed in the EML. However, this analysis excludes several later-expiring device patents potentially relevant to tiotropium, as the EML listing is for “Powder for inhalation, capsule” or the solution, and the later-expiring patents apply to other forms and/or methods of use for indications not on the EML.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Albania	3	02/04/2023	EP03718724	No
Belarus	3	02/04/2023	EA200401304	No
Brazil	1	10/03/2023	BR0308513	No
Chile	3	31/12/2023	CL200102449	No
China	4	02/04/2023	CN03808025	No
Colombia	1	02/04/2023	CO04100971	No
Cuba	1	11/04/2023	CU20030082	No
Egypt	1	09/04/2023	EG2003000332	No
Indonesia	3	02/04/2023	IDW00200402207	No
Kazakhstan	1	28/09/2026	EA200200551	No
Kosovo	1	02/04/2023	KV222	No
Malaysia	3	09/04/2023	MYPI20031314	No
Mexico	5	02/08/2026	MX2008001506	No
Montenegro	3	02/04/2023	MEP47108	No
Morocco	1	08/04/2023	MA27103	No
North Macedonia	3	02/04/2023	EP03718724	No
Pakistan	2	08/04/2023	PK301/2003	No
Philippines	5	02/08/2026	PH12008500316	No
Russian Federation	4	02/08/2026	RU2008108302	No
Serbia	3	10/03/2023	RSP20040826	No

South Africa	5	02/08/2026	ZA200800186	No
Thailand	3	10/04/2023	TH0301001354	No
Turkey	3	02/04/2023	EP03718724	No
Ukraine	3	02/04/2023	UA20041109153	No
United Arab Emirates	2	02/04/2023	AE320-2004	No
Uzbekistan	2	02/04/2023	UZ20040420	No
Venezuela	3	09/04/2023	VE2003000585	No
Viet Nam	2	02/04/2023	VN1200401178	No

Tiotropium Therapeutic Alternative: Acclidinium

The EML lists acclidinium as a therapeutic alternative to tiotropium. There are 25 jurisdictions with 54 active filings. The first date of expiration was 2020; the latest patent is estimated to expire in 2030. Note: In general, we have not analyzed the applicability of patents that have been identified by our data sources as members of patent families relevant to drugs listed in the EML. However, this analysis excludes several later-expiring device patents potentially relevant to acclidinium, as the EML listing is for “Powder for inhalation, capsule” or the solution, and the later-expiring patents apply to other forms and/or methods of use for indications not on the EML.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Albania	3	3/13/29	EP15173011	No
Bolivia (Plurinational State of)	1	3/12/29	BOSP00742009	No
Bosnia and Herzegovina	3	3/13/29	EP15173000	No
Brazil	1	3/13/29	BRPI0905775	No
Chile	3	3/12/29	CL2009000602	No
Ecuador	2	3/13/29	ECSP10010300	No
Egypt	2	3/13/29	EGPCT/1503/2010	No
Indonesia	1	3/13/29	IDW00201002447	No
Malaysia	2	3/13/29	MYPI2010004245	No
Mexico	3	3/13/29	MX2010008235	No
Montenegro	1	3/13/29	MEP16115	No
Nigeria	1	3/13/29	NG/C/2010/008235	No
North Macedonia	3	3/13/29	EP15173011	No

Pakistan	1	3/12/29	PK2242009	No
Peru	1	3/11/29	PE2018001507	No
Philippines	2	3/13/29	PH12010501717	No
Russian Federation	5	9/23/30	RU2010141333	No
Serbia	5	3/13/29	EP15173011	No
South Africa	2	3/13/29	ZA201003900	No
Thailand	2	3/6/29	TH0901000973	No
Turkey	4	3/13/29	EP15173000	No
Ukraine	3	3/13/29	UAA201012043	No
Uruguay	1	2/7/28	UY30901	No
Venezuela	1	3/2/29	VE2009000392	No
Viet Nam	1	3/13/29	VN1201002470	No

Tiotropium Therapeutic Alternative: Glycopyrronium

The EML lists glycopyrronium as a therapeutic alternative to tiotropium. There are 7 jurisdictions with 8 active filings. The first date of expiration was 2016; the latest patent is estimated to expire in 2028. Note: In general, we have not analyzed the applicability of patents that have been identified by our data sources as members of patent families relevant to drugs listed in the EML. However, this analysis excludes several later-expiring device patents potentially relevant to glycopyrronium, as the EML listing is for “Powder for inhalation, capsule” or the solution, and the later-expiring patents apply to other forms and/or methods of use for indications not on the EML.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Brazil	1	4/29/25	BRPI0510500	No
India	1	4/29/25	IN4400/CHENP/2006	No
Mexico	2	10/27/26	MX2012008068	No
Russian Federation	1	9/23/28	RU2006142322	No
Serbia	1	11/23/25	EP10151576	No
South Africa	1	4/29/25	ZA200609350	No
Turkey	1	11/23/25	EP10151576	No

Tiotropium Therapeutic Alternative: Umeclidinium

The EML lists umeclidinium as a therapeutic alternative to tiotropium. There are 64 jurisdictions with 89 active filings. The first date of expiration is expected to occur in 2025;

the latest patent is estimated to expire in 2030. Note: In general, we have not analyzed the applicability of patents that have been identified by our data sources as members of patent families relevant to drugs listed in the EML. However, this analysis excludes several later-expiring device patents potentially relevant to umeclidinium, as the EML listing is for “Powder for inhalation, capsule” or the solution, and the later-expiring patents apply to other forms and/or methods of use for indications not on the EML.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Determined to Be Subject to Licensing Agreement or Other Commitment
Algeria	1	4/27/25	DZ2006000574	No
Argentina	1	4/25/25	ARP050101627	No
Azerbaijan	2	12/12/25	EA200601991	No
Belarus	2	4/27/30	EA200601991	No
Benin	2	4/27/25	OA1200600360	No
Botswana	1	4/27/25	AP2006003746	No
Brazil	1	4/27/25	BRPI0510170	No
Burkina Faso	2	4/27/25	OA1200700464	No
Cameroon	2	4/27/25	OA1200700464	No
Central African Republic	2	4/27/25	OA1200600360	No
Chad	2	4/27/25	OA1200600360	No
Chile	1	4/25/25	CL200500963	No
China	1	4/27/25	CN201010558078	No
Colombia	1	4/27/25	CO06108728	No
Congo	2	4/27/25	OA1200700464	No
Côte d'Ivoire	2	4/27/25	OA1200600360	No
Ecuador	1	4/27/25	ECSP066940	No
Egypt	1	4/27/25	EG892/2006	No
Equatorial Guinea	2	4/27/25	OA1200600360	No
Eswatini	1	4/27/25	AP2006003746	No
Gabon	2	4/27/25	OA1200700464	No
Gambia	1	4/27/25	AP2006003746	No
Ghana	1	4/27/25	AP2006003746	No
Guinea	2	4/27/25	OA1200600360	No
Guinea-Bissau	2	4/27/25	OA1200700464	No

India	1	4/27/25	IN5413/DELNP/2006	No
Indonesia	1	4/27/25	IDW00200602957	No
Jamaica	1	9/22/29	JM18/1/5346	No
Kazakhstan	2	4/27/30	EA200601991	No
Kenya	1	4/27/25	AP2006003746	No
Lesotho	1	4/27/25	AP2006003746	No
Malawi	1	4/27/25	AP2006003746	No
Malaysia	1	4/25/25	MYPI20051806	No
Mali	2	4/27/25	OA1200700464	No
Mauritania	2	4/27/25	OA1200600360	No
Mexico	1	4/27/25	MXPA06012405	No
Moldova, Republic of	2	4/27/30	EA200601991	No
Morocco	1	4/27/25	MA29426	No
Mozambique	1	4/27/25	AP2006003746	No
Namibia	1	4/27/25	AP2006003746	No
Niger	2	4/27/25	OA1200600360	No
Nigeria	1	4/25/25	NG176/05	No
Pakistan	1	4/27/24	PK3532005	No
Peru	1	4/25/25	PE2005000457	No
Philippines	2	4/27/25	PH12012500975	No
Russian Federation	2	7/30/29	EA200601991	No
Senegal	2	4/27/25	OA1200600360	No
Sierra Leone	1	4/27/25	AP2006003746	No
South Africa	1	4/27/25	ZA200608565	No
Sri Lanka	1	4/27/25	LK14227	No
Sudan	1	4/27/25	AP2006003746	No
Tajikistan	2	4/27/25	EA201100019	No
Tanzania	1	4/27/25	AP2006003746	No
Thailand	1	4/25/25	TH0501001846	No
Togo	2	4/27/25	OA1200700464	No
Trinidad and Tobago	1	4/27/25	TT/A/2006/00208	No
Turkey	2	4/27/25	EP12170402	No
Uganda	1	4/27/25	AP2006003746	No

Ukraine	1	4/27/25	UAA200611253	No
United Arab Emirates	1	4/26/25	GC2005/4585	No
Venezuela	1	4/25/25	VE768/2005	No
Viet Nam	2	4/27/25	VN1200901741	No
Zambia	1	4/27/25	AP2006003746	No
Zimbabwe	1	4/27/25	AP2006003746	No